References and Suggested Reading


Hammers HJ, Plimack E, Infante J, et al. Updated results from a phase I study of nivolumab (NIVO) in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC): The CheckMate016 study. Abstract 1062P. Presented at the European Society of Medical Oncology Meeting; October 7-11, 2016; Copenhagen, Denmark.

Hodi S, Postow MA, Chesney JA, et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate069). Abstract 9518. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL.

Hoffman-Censits JH, Grivas P, Van Der Heijden MS, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). Abstract 335. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium; January 7-9, 2016; San Francisco, CA.

Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. *J Clin Oncol.* 2015;33:3193-3198.

Janjigian YY, Bendell JC, Calvo E, et al. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). Abstract 4010. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL.


Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate067). Abstract CT075. Presented at the American Association for Cancer Research Annual Meeting; April 3, 2017; Washington, DC.


Rosenberg JE, Petrylak DP, Van Der Heijden MS, et al. PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). Abstract 104. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL.


Socinski M, Creeelan B, Horn L, et al. NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)–positive NSCLC. Abstract LBA7_PR. Presented at the European Society of Medical Oncology Meeting; October 7-11, 2016; Copenhagen, Denmark.


Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate067). Abstract 9505. Presented at the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate067). Late Breaking Abstract 1. Presented at the American Society of Clinical Oncology Annual Meeting; May 29 – June 2, 2015; Chicago, IL.